Paragonix to Spotlight Breakthrough Research in Solid Organ Transplantation at the 2025 World Transplant Congress
A series of oral and poster presentations at the conference will showcase new clinical findings from the GUARDIAN Registries, in addition to independent clinical analyses, emphasizing the impact of controlled hypothermic preservation on post-transplant outcomes. These studies span multiple organ systems and demonstrate the growing reach and efficacy of Paragonix's market leading Advanced Organ Preservation solutions.
Paragonix will be featured in two oral presentations and five poster sessions throughout the week, including:
Additionally, Paragonix will be hosting an industry symposium focused on abdominal transplantation:
Symposium: Preservation Innovations – Propelling Abdominal Transplantation Forward
This event will feature leading transplant experts sharing the latest insights from the GUARDIAN-Liver Registry, case studies on advanced donor liver preservation, and field insights of the KidneyVault Portable Renal Perfusion System, a self-regulated perfusion system that aims to modernize the landscape of kidney transplantation.
'Our presence at WTC 2025 represents a significant milestone in the advancement of our pan-organ transplant preservation technologies and procurement services,' said Dr. Lisa Anderson, President of Paragonix Technologies. 'We're honored to collaborate with leading clinicians and researchers to explore the clinical impact of these innovations and continue to push the boundaries of what's possible in transplant medicine across all solid organs.'
To visit the Paragonix Technologies exhibit and meet members of their team at WTC, visit booth #314. For more information about Paragonix, visit www.paragonix.com.
About Paragonix Technologies
Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation.
A Getinge company, Paragonix Technologies provides Advanced Organ Preservation ('AOP') devices that safeguard donor organs during the journey between donor and recipient patients. Their FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with a novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit www.paragonix.com.
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile processing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.
Connect with us on LinkedIn: Paragonix Technologies
Find us on YouTube: Paragonix SherpaPak
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Organ Care Products Market Valuation Set to Surpass US$ 812.12 Million By 2033
Innovation now defines the organ care products market. Advanced perfusion and portable systems are actively expanding the donor organ pool, tackling immense waiting lists driven by chronic diseases and dramatically improving success rates for vital transplants. Chicago, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The global organ care products market was valued at US$ 199.20 million in 2024 and is expected to reach US$ 812.12 million by 2033, growing at a CAGR of 16.90% during the forecast period 2025–2033. The current scenario in the organ care products market is one of explosive growth, fueled by the twin engines of unprecedented global demand and transformative technology. In 2024, the U.S. performed a record 48,149 transplants, yet this barely meets the need, as regions like Eurotransplant still have over 13,570 patients on waiting lists. This profound supply-demand imbalance is accelerating a fundamental shift away from traditional static cold storage towards advanced perfusion and assessment systems. These technologies are directly addressing the critical issue of organ non-utilization, aiming to convert a portion of the thousands of organs discarded annually into life-saving opportunities, thereby changing the entire calculus of transplantation. Request Sample Pages: This evolution is being aggressively capitalized upon by key industry players through strategic expansion and is buoyed by substantial investment. Recent developments, such as Paragonix's EU MDR certification for five devices in March 2025 and its rapid U.S. commercial expansion, highlight a fierce race to capture market share. The market's momentum is further underwritten by significant capital influx, from government initiatives like the $67 million allocated for U.S. transplant system modernization in FY2025 to targeted research funding from organizations like Enduring Hearts. The current scenario is therefore not just about growth, but about a well-funded, strategic push to commercialize innovation on a global scale. Key Findings in Organ Care Products Market Market Forecast (2033) US$ 812.12 million CAGR 16.90% Largest Region (2024) North America (56%) By Organ Type Kidney (28%) By Product Type Trolly (53%) Top Drivers Rising global incidence of chronic diseases fuels organ transplant demand. Technological advancements in organ preservation systems improve transplant success rates. Favorable reimbursement policies encourage organ transplant procedures, boosting market growth. Top Trends Emergence of normothermic machine perfusion for real-time organ function assessment. Development of smaller, portable organ preservation devices for easier transport. Focus on developing organ-specific preservation solutions for better patient outcomes. Top Challenges Complex ethical and logistical hurdles in organ procurement and allocation. Unprecedented Transplant Volumes Are Fueling Robust Market Expansion and Demand The foundational driver for the organ care products market is the sheer volume of surgical procedures, which continued its upward trajectory through 2024. In the United States alone, a record of over 48,000 organ transplants were performed. This milestone was confirmed with a final tally of 48,149 procedures for the year, marking the first time the nation has exceeded this figure. This represents an impressive average of 132 organ transplants performed each day in the U.S. throughout 2024. Critically, 2024 marked the 14th consecutive year of growth in the number of organs recovered for transplants in the U.S., signaling a sustained and reliable increase in the core activity that underpins the market. This trend is not isolated; globally, organ transplantation activities saw a notable increase in 2023, which has set a strong precedent for continued growth in 2024 and beyond. In Europe, the eight Eurotransplant countries allocated 7,150 organs from deceased donors in 2024, while in China, a remarkable 24,684 transplant surgeries were performed during the same year, showcasing the truly global nature of this expansion. The Critical Role of Organ Procurement in Shaping Market Dynamics The availability and procurement of donor organs represent the starting point for the entire transplantation value chain, directly influencing the organ care products market. In the United States, 55 dedicated organ procurement organizations (OPOs) were operational as of October 2024, forming the backbone of the recovery network. In 2024, these U.S. OPOs successfully recovered over 45,000 organs for transplant procedures. This was made possible by the 16,989 Americans who became deceased organ donors, a testament to growing awareness and consent. These efforts were supplemented by more than 7,000 living donors in the U.S. in 2024. An interesting demographic trend shows that nearly 8,200 of the deceased donors in the U.S. in 2024 were aged 55 and older, highlighting the expanding criteria for donation. In the United Kingdom, from April 2023 to March 2024, there were 1,510 deceased organ donors and 938 living organ donors. Across the Eurotransplant region, organs were sourced from 2,181 deceased donors in 2024. Meanwhile, China recorded 6,744 cases of organ donations in 2024, with the number of registered organ donors soaring to over 7.05 million by early 2025, indicating massive future potential. Organ-Specific Procedural Growth Creates Niche Opportunities Within the Market A deeper analysis of procedural data reveals that growth is not uniform across all organ types, creating distinct and lucrative opportunities within the organ care products market for specialized preservation technologies. In the United States during 2024, cardiac procedures were significant, with 4,572 heart transplants performed. Thoracic procedures were also prominent, as the number of lung transplants reached 3,340. Abdominal transplants, which constitute the largest segment, saw a total of 11,458 liver transplants and an impressive 27,759 kidney transplants performed in the U.S. in 2024. This high volume in renal transplantation underscores the demand for reliable kidney preservation solutions. Furthermore, specialized procedures are gaining traction; in the UK, for instance, 65 Donation after Circulatory Death (DCD) heart transplants took place in the 2023/24 period, a complex procedure that relies heavily on advanced preservation technology to ensure viability. Diverse Regional Landscapes Present Unique Challenges and Growth Avenues The global organ care products market is characterized by significant regional variations in infrastructure, regulatory frameworks, and donation patterns. China's market, for example, is notable for its scale; as of early 2025, there have been more than 58,000 cumulative organ donations to date. The country has also recorded over 63,000 body donations and 110,000 corneal donations as of 2025, pointing to a well-established and growing donation culture. In the UK, the data from 2023-2024 provides a detailed look at the procurement funnel, with 772 donors after brain death (DBD) and 738 donors after circulatory death (DCD). That year, there were 6,794 potential deceased organ donors identified in the UK, of whom 6,421 were formally referred as potential donors. From that pool, donation requests were made to families in 3,107 cases, ultimately resulting in 1,880 consented donors, illustrating the multi-step process where advanced care technology can play a role in boosting confidence and consent. Groundbreaking Product Innovation and Regulatory Wins Propel Market Leaders Forward Innovation is the lifeblood of the organ care products market, with regulatory approvals serving as key milestones that unlock new commercial opportunities. In October 2024, Paragonix Technologies achieved a major milestone with FDA 510(k) clearance for its KidneyVault portable renal perfusion system. This strategic clearance solidified Paragonix as the only company possessing U.S. regulatory clearances for advanced preservation devices for all five solid organs used in transplants. Earlier in the year, in June 2024, the company launched its PancreasPak, the world's first FDA-cleared preservation device for donor pancreases, with pre-orders beginning on June 27, 2024, and full commercial availability planned for September 1, 2024. In April 2024, Paragonix also announced the full U.S. commercial launch of its BAROguard Donor Lung Preservation System. During its limited market release, 5 of the top U.S. thoracic transplant centers had already deployed the BAROguard System. The momentum continued into 2025, when Paragonix received EU MDR approval for five of its organ preservation devices in March. These specific product approvals stood out in a year where the FDA approved a total of just 21 medical devices overall in 2024. Strong Financial Performance and Strategic Investments Signal a Healthy Marketplace The financial health and strategic initiatives of key industry players in the organ care products market provide compelling evidence of a vibrant and growing market. XVIVO Perfusion reported strong results for 2024, with net sales amounting to SEK 822.4 million for the full year. The fourth quarter of 2024 was particularly robust, with net sales reaching SEK 227.6 million. The company's profitability was also solid, with an operating income (EBIT) for Q4 2024 of SEK 15.5 million and an operating income before depreciation and amortization (EBITDA) of SEK 51.9 million. Strong operational execution led to a cash flow from operating activities of SEK 62.1 million in Q4 2024, and the company posted a net profit for the full year 2024 of SEK 172.2 million. On the utilization front, Paragonix preservation devices have been used in over 10,000 transplant cases globally as of March 2025, demonstrating deep market penetration. Specifically, the Paragonix SherpaPak and LUNGguard systems are utilized at over 150 transplant centers globally, including over 40 transplant centers in the EU, highlighting the company's expanding international footprint. Modernization Initiatives and Research Funding Pave the Way for Future Growth Substantial government and institutional investments in research and system modernization are creating a fertile ground for the future growth of the organ care products market. The U.S. Senate Appropriations Committee has included a significant $67 million in funding for the Organ Procurement and Transplantation Network (OPTN) Modernization Initiative for fiscal year 2025. This represents a $13 million increase over FY 2024 levels. The FY24 funding package had already included an additional $23 Million for the HRSA OPTN Modernization Initiative, bringing the total for that year to $52 Million. In 2024, the Mid-America Transplant Foundation's Clinical Innovation Fund began offering awards of up to $150,000 per year for three years to spur new research. The American Society of Transplantation (AST) is furthering this by offering a research grant of $75,000 for one year, with a term starting January 1, 2025. The International Society for Heart & Lung Transplantation is offering a grant of up to $75,000 for research into DCD heart transplantation, with recipients to be announced in January 2025, and a second grant of up to $37,500 for acellular Ex Vivo Lung Perfusion (EVLP) research. In 2024, the Scandiatransplant Research grant also supported two projects with 100,630 DKK and 260,000 DKK, respectively. Need a Customized Version? Request It Now: Addressing Organ Utilization and Waiting Lists Remains a Core Market Imperative The persistent challenges of organ non-utilization and extensive patient waiting lists serve as powerful catalysts for the organ care products market, driving the need for technologies that can preserve, assess, and improve marginal organs. In 2024, a concerning 9,275 recovered kidneys in the U.S. were ultimately not used for transplant, continuing a trend that highlights a critical gap between recovery and utilization. To combat this, OPOs have hosted eleven Transplant Growth Collaborations over the past year to share successful practices. Advanced perfusion is emerging as a key solution; a 2024 study of 803 transplantations, of which 174 received Normothermic Machine Perfusion (NMP), showed NMP was associated with a reduced need for early relaparotomy in liver transplants. Another 2024 study involving 118 NMP-treated livers matched with 236 preserved with static cold storage, and a cohort matching 37 NMP-DCD livers with 74 using static cold storage, are providing crucial data on efficacy. Global Organ Care Products Market Major Players: Bridge to Life Ltd. TransMedics Inc. Organ Recovery system XVIVO Preservation Solution Inc. Paragonix technologies and IGL OrganOx Limited Other Prominent Players Key Market Segmentation: By Organ Type Kidney Liver Heart Lungs Others By Product Type Trolly Portable By Region North America Europe Asia Pacific Middle East Africa South America Request a Personalized Report Walkthrough with Our Research Team: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business Wire
Guardian Pharmacy Services Strengthens Pacific Northwest Presence with Acquisition of Oregon-based Managed Healthcare Pharmacy
ATLANTA--(BUSINESS WIRE)-- Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care (LTC) pharmacy services companies, today announced its acquisition of Managed Healthcare Pharmacy, a leading LTC pharmacy in Oregon with locations in Eugene and Medford. This transaction marks a significant milestone for Guardian, establishing its first physical footprint in the state and expanding its presence in the Pacific Northwest. The newly acquired pharmacy serves residents in assisted living and behavioral health communities, as well as individuals with intellectual and developmental disabilities. "This acquisition allows us to expand our presence in the Pacific Northwest with a team already known for exceptional care and trusted partnerships,' said Fred Burke, president and CEO of Guardian Pharmacy Services. Established in 1991, Managed Healthcare Pharmacy is one of Oregon's largest LTC pharmacies, with a strong track record of service in LTC communities across the state and into Washington. All existing leadership and staff will remain in place, and the pharmacy will continue operating under its existing name. 'We continue to grow in regions where senior living operators value more dependable, high-touch support from established LTC pharmacies,' said Fred Burke, president and CEO of Guardian Pharmacy Services. 'Managed Healthcare Pharmacy has built a strong reputation in Oregon and Washington for its clinical expertise and deep commitment to the communities it serves. This acquisition allows us to expand our presence in the Pacific Northwest with a team already known for exceptional care and trusted partnerships.' As with Guardian's other acquisitions, Managed Healthcare Pharmacy will benefit from the company's locally operated business model, supported by its centralized corporate team. This enables the local pharmacy to remain focused on exceptional customer service and the specialized needs of the communities and residents they serve, while Guardian assists with the many complex behind-the-scenes business functions, including data analytics, HR, IT, payor relations, national sales and more. About Guardian Pharmacy Services Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy services companies. Through its locally-based business model, Guardian partners with long-term care facilities ('LTCFs') to deliver medications and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. With a growing network of more than 50 pharmacies nationwide, Guardian is dedicated to providing exceptional service to over 189,000 residents and approximately 7,000 LTCFs across 38 states (as of March 31, 2025). Forward-Looking Statements This press release contains forward-looking statements, including statements regarding our anticipated growth and expectations related to synergies and integration of the acquired pharmacy's operations and employees. These statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, including those described in Guardian's periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission from time to time, and which are publicly available at and via our website, Actual results may differ materially from those expressed or implied in these statements. Guardian undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Business of Fashion
2 days ago
- Business of Fashion
China's Fast-Fashion Capital Slows Down Under Trump's Trade War
Lingering at a day market for labourers in Panyu, an urban village on the outskirts of Guangzhou, Ms Qiu looks dejected. She is looking for a local factory that will hire her for the day to sew clothes – cheap tops and dresses that will be churned out on to China's e-commerce platforms, or bundled up for export to western shoppers. But she is not having much luck. 'The whole industry is struggling, and now there is a high tariff on Chinese goods because of the trade war. Many foreign clients have decreased their orders from China,' she says, declining to give her first name. Guangzhou, China's southern metropolis and the capital of Guangdong province, is home to nearly 20 million people. It is also the humming, whirring and buzzing heart of the global fast fashion industry. In its urban villages, ramshackle settlements that have been absorbed into the city's sprawl, millions of workers toil day and night in informal workshops to produce cheap garments. In one small, crowded factory, women sit behind sewing machines next to teetering mountains of starched black tutus. In another, pink denim jeans destined to be sold on fast fashion website Shein are piled high on every available worktop. Every morning, workers gather in informal labour markets like the one in Panyu to see if they can find work for the day sewing on hundreds of buttons, or ironing hundreds of collars. Depending on the complexity of the task, workers earn between one and 10 yuan per item, toiling for long hours in cramped conditions. 'This is hard-earned money,' says a worker in his 60s in Datang, another urban village about ten miles north of Panyu. Ironing jackets at 8am, before packaging them up to be exported, the man, who declined to give his name, was part-way through a shift that had started at 11pm the night before. He earned two yuan per jacket, he said. More than a dozen garment workers interviewed by the Guardian all said that a normal working day was 10 to 12 hours, with some saying they only took one rest day each month. 'Little Room for Profit' While China's domestic e-commerce market has boomed in recent years, it is overseas orders that keep the factory lights on. Around one-quarter of the more than $100bn of textiles and apparel imported to the US came from China last year. Guangdong alone exported more than $7bn, according to data from the Global Trade & Industry Growth Lab by Sinoimex, a commercial data firm. But in April, Donald Trump, the US president, launched a trade war with China, which sent shockwaves through the global economy. Tariffs on Chinese goods reached 145 percent, with China responding with similar duties and trade restrictions, before the two countries agreed to a 90-day pause in May. With a 12 August deadline looming to reach a deal, workers in Guangzhou are wondering whether or not they'll be able to keep selling clothes to Americans. In Panyu, Yang Ruiping has run his small clothes factory, which specialises in tops and employs about 20 people, for two decades. About 30 percent of his orders are exported, mostly to Shein and Amazon, down from more than 50 percent before the pandemic. Although the pause in the trade war has eased the pressure on his business slightly, he still has 'little confidence in the US'. 'In the recent US-China trade war, if the tariffs go up, we need to lower the production costs to combat it,' he says. 'It leaves little room for profit'. With no room to cut wages any lower, Yang says he is already losing money on every top he sells. He keeps accepting the orders in order to keep the factory open, but with the domestic market becoming increasingly competitive, he is aware he might not be able to operate much longer. Shein is everywhere in Panyu. The China-founded, Singapore-headquartered company revolutionised the garment industry in Guangzhou, allowing small manufacturers like Yang to sell directly to western customers, and offering shoppers rock-bottom prices. While big high street brands operate larger, dedicated factories, Shein places small batch orders directly with independent manufacturers, ramping up production for the designs that sell well online. The flexibility of this model has fuelled the company's meteoric rise. Shein accounts for about 50 percent of the US fast fashion industry, according to Bloomberg Second Measure, a data analytics firm. The company's growth has also been thanks to a loopholes in the US customs regime, which allowed low-value goods to be imported free. In 2022, over 30 percent of all the small packages imported under the so-called 'de minimis' exemption came from Shein and Temu, another Chinese e-commerce company. On 2 May, Trump closed that loophole for goods from China and Hong Kong. This week, he expanded that ban to goods from all countries, meaning that suppliers can't avoid tariffs by shipping via third countries. A recent analysis by Reuters found that prices on Shein increased by an average of 23 percent between 24 April and 22 July. The US market is 'volatile and risky,' says Peng Jianshen, the boss of a medium-sized denim clothes factory in Zengcheng, another of Guangzhou's urban villages. 'When tariffs were suddenly increased, the entire US-focused production stopped. No one dared to continue'. Experts say that the uncertainty of the trade war could have a negative impact on working conditions, encouraging workers to add hours to their already punishingly long shifts. 'Generally, when we're talking about the garment industry in China, workers don't have rest days,' says Li Qiang, the founder of China Labor Watch, a US-based NGO. 'They're paid by piece rate. So they work as much as possible when the orders are still there.' But factory bosses in Guangzhou say the trade war is only the latest in a series of problems facing their industry. Global conflicts and low consumer spending in China mean that it's hard to pivot away from the US and towards other markets. Li Jun, a chain-smoking factory boss, runs a denim clothing factory that sells jeans to Russia. He says the economic impact of the war in Ukraine, plus the fact that many of his would-be customers have been drafted to fight in the conflict, have been bad for business. 'The economy is not doing well anywhere,' he says. 'A lot of factories are shutting down.' At his peak he was exporting 100,000 pairs of jeans per month, with more than half going to Russia, but now it's 30,000 to 40,000 pairs each month, meaning that he just about breaks even. Manufacturers in places like Guangzhou have long been the engine room of China's growth. But in recent years, keen to shed the label of being the world's factory, Beijing has been pouring all its political and economic support into hi-tech industries, such as artificial intelligence and semiconductors. 'The Chinese government no longer supports these kinds of light industries or small individual businesses,' Li says. 'It's really hard to keep things going'. By Amy Hawkins Learn more: Trump to Levy 25% Tariffs on Japan, South Korea in August The 25 percent rates do not include any sectoral-specific tariffs that the Trump administration would separately implement on goods imported in key industries.
